Clinical Trial Update: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of Etrumadenant and Zimberelimab in Dedifferentiated liposarcoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Etrumadenant (etrumadenant)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Dedifferentiated Liposarcoma, Soft Tissue Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING